Dataset Information

1000 Genomes Phase 1 Analysis

ABSTRACT: Variant discovery and individual genotypes for 1092 individuals from the 1000 Genomes Project Phase 1 data release. Site discovery and genotyping for SNPs are based on both low coverage and exome capture sequence data for short indels, only low coverage data, and for large deletions, only the 946 individuals with Illumina low coverage sequence data are used. As a final step, statistical genotype imputation using the linkage disequilibrium between nearby sites refines the individual genotypes and merges information from all three variant types.

INSTRUMENT(S): Illumina Genome Analyzer II, 454 GS FLX, AB SOLiD System, Illumina Genome Analyzer, AB SOLiD System 2.0

ORGANISM(S): Homo Sapiens

SUBMITTER: The 1000 Genomes Project Consortium

PROVIDER: PRJEB4019 | EVA | 2014-10-20

REPOSITORIES: EVA

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	ALL.chr1.integrated_phase1_v3.20101123.snps_indels_svs.genotypes.vcf.gz	Vcf
	ALL.chr10.integrated_phase1_v3.20101123.snps_indels_svs.genotypes.vcf.gz	Vcf
	ALL.chr11.integrated_phase1_v3.20101123.snps_indels_svs.genotypes.vcf.gz	Vcf
	ALL.chr12.integrated_phase1_v3.20101123.snps_indels_svs.genotypes.vcf.gz	Vcf
	ALL.chr13.integrated_phase1_v3.20101123.snps_indels_svs.genotypes.vcf.gz	Vcf

Items per page:

1 - 5 of 25

Similar Datasets

Project description:Next generation sequencing platforms have become essential tools for understanding DNA in a wide range of contexts. Their success heavily relies on the accuracy, sensitivity and specificity of methods used to discern differences between the reference genome and genomes under investigation. Here we compare the relative performances of five popular single nucleotide variant callers with and without their associated recommended hard filtering criteria. We compare: FreeBayes; the Genome Analysis Toolkit’s Haplotype Caller and Unified Genotyper; SAMtools; and VarScan. We tailor this comparison to suit smaller projects with modest sample numbers (n = 10) and coverage (~10X) to fill a current gap in the literature. Other comparison studies are generally applicable only to larger projects in model species, where there is access to large amounts of sequencing data and curated callsets for base and variant quality score recalibration. We estimated the accuracy, sensitivity and specificity of each pipeline according to the genotype concordance rate and number with the “truth” dataset for 10 canine samples. The truth dataset was defined as genotypes obtained from the CanineHD BeadChip array. Whole genome sequencing data was performed on the Illumina HiSeq2000 or HiSeq2500 platform as 100-101 base pair, paired end reads to an average sample coverage of 10.3X. Apart from GATK Haplotype Caller, applying recommended hard filters did not improve the performance of genotyping concordance at the tested levels of minimum coverage. The default VarScan pipeline with no additional filters applied (VarScan uses SAMtools mpileup, without base alignment quality computation) generally outperformed other callers in terms of accuracy, sensitivity and specificity. The results of this study demonstrate that hard filtering of variant calls from low-powered genome studies can impair accuracy, sensitivity and specificity of callsets and provides some benchmark performance metrics on a range of low coverage levels.

Project description:Inter-individual DNA methylation variations were frequently hypothesized to alter individual susceptibility to Type 2 Diabetes Mellitus (T2DM). Sequence-influenced methylations were described in T2DM-associated genomic regions, but evidence for direct, sequence-independent association with disease risk is missing. Here we explore disease-contributing DNA methylation through a stepwise study design: first, a pool-based, genome-scale screen among 1,169 case and control individuals revealed an excess of differentially methylated sites in genomic regions that were previously associated with T2DM through genetic studies. Next, in-depth analyses were performed at selected top-ranked regions. A CpG site in the first intron of the FTO gene showed small (3.35%) but significant (p=0.000021) hypomethylation of cases relative to controls. The effect was independent of the sequence polymorphism in the region and persists among individuals carrying the sequence risk alleles. The odds of belonging to the T2DM group increased by 6.1% for every 1% decrease in methylation (OR=1.061, 95% CI: 1.032-1.090), and the sensitivity (AUC = 0.638, 95% CI: 0.586-0.690), (Males=0.675, Females=0.609), was better than of the strongest known sequence variant. Furthermore, a prospective study in an independent population cohort revealed significant hypomethylation of young individuals that later progressed to T2DM, relative to the individuals that stayed healthy. Further genomic analysis revealed co-localization with gene enhancers and with binding sites for methylation-sensitive transcriptional regulators. The data showed that low methylation level at the analyzed sites is an early marker of T2DM, and suggest a novel mechanism by which early-onset, inter-individual methylation variation at isolated non-promoter genomic sites predisposes to T2DM. Five pools of DNA samples consist of 710 T2DM patients and 459 control individuals were analyzed for average methylation levels at 1,461,753 DNA genomic fragments containing 3,359,645 CpG methylation sites using four SNP arrays for each sample, two 'genomic' (before treatment) replicates and two MSRE (treatment with a cocktail of five methyl-sensitive-restriction-enzyme) replicates. The analysis was done using the Affymetrix SNP 6.0 array.

Dataset Information

1000 Genomes Phase 1 Analysis

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets